Literature DB >> 12632030

Recombinant activated factor VII combined with local measures in preventing bleeding from invasive dental procedures in patients with Glanzmann thrombasthenia.

Ampaiwan Chuansumrit1, Monthon Suwannuraks, Nantana Sri-Udomporn, Bunchoo Pongtanakul, Surapon Worapongpaiboon.   

Abstract

Recombinant activated factor VII (rFVIIa), combined with local measures of fibrin glue and a celluloid splint, preventing bleeding from four invasive dental procedures is reported. A single dose of 180-200 micro g/kg was successfully used in three surgical removals of impacted teeth. Four doses of rFVIIa were required in another full mouth treatment of extraction, pulpotomy, filling and the stainless steel crowning of 13 teeth. The repeated dose of rFVIIa was given whenever the bleeding complication was visualized. It is cost-effective for preventing external bleeding. Additionally, an oral rinsing solution of tranexamic acid (25 mg/kg) was given three times a day for 7 days. In conclusion, rFVIIa has been shown to be an effective alternative to platelet concentrate in patients with Glanzmann thrombasthenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12632030     DOI: 10.1097/00001721-200302000-00011

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  6 in total

Review 1.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 2.  The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

3.  Recombinant coagulation factor VIIa--a novel haemostatic agent in scoliosis surgery?

Authors:  Maciej Kolban; Ina Balachowska-Kosciolek; Michal Chmielnicki
Journal:  Eur Spine J       Date:  2005-08-17       Impact factor: 3.134

Review 4.  Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.

Authors:  Anthony E Pusateri; Myung S Park
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

Review 5.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007

6.  Glanzmann's Thrombastenia: The Role of Tranexamic Acid in Oral Surgery.

Authors:  Rocco Franco; Michele Miranda; Laura Di Renzo; Antonino De Lorenzo; Alberta Barlattani; Patrizio Bollero
Journal:  Case Rep Dent       Date:  2018-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.